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ABSTRACT OF THESIS 
 
 
 
 
 
DUAL LOX/COX INHIBITION: A NOVEL STRATEGY TO PREVENT 
NEUROVASCULAR LEAKAGE IN EPILEPSY 
 
 
Epilepsy affects 3.4 million patients in the USA and is characterized by recurring seizures. 
The blood-brain barrier is leaky in epilepsy and may contribute to seizure progression but 
the mechanisms which cause this leakage are not fully understood. We hypothesized that 
seizures trigger LOX- and COX-mediated blood-brain barrier leakage and that dual 
LOX/COX inhibition prevents barrier leakage in vivo. To test this hypothesis, we 
administered either the dual LOX/COX inhibitor licofelone or a combination of the 5-LOX 
inhibitor zileuton and the COX-2 inhibitor celecoxib to rats that experienced status 
epilepticus (SE). Serum and brain capillaries were isolated 48 hours after SE and serum 
S100β levels were measured and Texas Red™ leakage rates were determined. Dual 
inhibition of 5-LOX and COX prevented serum S100β elevations observed in SE rats in a 
dose-dependent manner with licofelone. Inhibition of 5-LOX and COX-2 with zileuton and 
celecoxib completely prevented serum S100β elevation. Texas Red™ leakage rates for SE 
rats were also reduced in a dose-depended manner with licofelone and reduced to control 
rates with zileuton and celecoxib. These data support our hypothesis that seizure-induced 
blood-brain barrier leakage is mediated by LOX and COX, and inhibition of these enzymes 
prevents barrier leakage. 
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1. Introduction 
 
1.1 Epilepsy Background 
Epilepsy is the 4th most prevalent neurologic disorder after migraine, stroke, and 
Alzheimer’s disease: affecting 50 million people worldwide and 3.4 million people in the 
USA have epilepsy and at least 30% of all epilepsy patients are refractory to drug 
therapy.2-5 The prevalence of epilepsy increased since the previous estimate of 3 million 
people which is thought to be due to population growth.2 One factor which may influence 
the incidence of epilepsy in the near future is the expanded definition of epilepsy 
established by the International League Against Epilepsy (ILAE).6 According to this 
definition, diagnosis of epilepsy requires one of the following: 1) two unprovoked seizures 
occurring at least 24 hours apart; 2) one unprovoked seizure with a high risk of recurrence; 
3) diagnosis of an epilepsy syndrome. The latter two characteristics were added to 
address a patient’s risk of future seizures and help epileptologists in treatment decisions.  
 Living with the threat of future seizures places a significant burden on daily life of 
epilepsy patients. Only Alzheimer’s disease, stroke, and migraines have higher disability-
adjusted life years (WHO Neurological Disorders: Public Health Challenges Report). In 
addition to disease burden, patients with epilepsy (PWE) are frequently afflicted with 
comorbid neurobehavioral conditions such as depression, suicidal ideation or attempt, 
cognitive impairment and drug abuse in addition to recurrent seizures.7-10 
 
1.2 Status Epilepticus Definition, Treatment, and Outcomes 
Status epilepticus (SE) was most recently redefined by the ILAE as “a condition 
resulting either from the failure of the mechanisms responsible for seizure termination or 
from the initiation of mechanisms which lead to abnormally prolonged seizures (after time 
point t1). SE is a condition that can have long-term consequences (after time point t2) …”11 
For generalized convulsive SE, seizures lasting > 5 minutes or recurrent seizure activity 
without recovery is used to operationally define SE.12 
Benzodiazepines are considered first line for initial pharmacologic treatment of SE 
and the specific agent and route of administration is determined based on factors such as 
the availability and timeliness of IV access and the age of the patient.12-15 For instance, 
while i.v. lorazepam may provide the shortest latency to seizure cessation, i.m. midazolam 
would be preferred for patients without prior i.v. access.16 If a patient is still seizing after 
20 minutes of benzodiazepine administration, a 2nd line agent such as i.v. fosphenytoin, 
i.v. valproic acid, or i.v. levetiracetam is administered. However, no trial has directly 
compared these three treatments head-to-head to determine which is best. The 
Established Status Epilepticus Treatment Trial (ESETT) is a triple blind randomized 
clinical trial currently underway to assess which of these three treatments is most effective 
in ending benzodiazepine-refractory SE.17,18 After a patient does not respond to a second 
anti-seizure drug, the SE is termed refractory and treatment varies widely by institution, 
but most commonly includes a continues i.v. infusion of an anesthetic agent such as 
midazolam, propofol, or a barbiturate.19,20 SE has far reaching outcomes for patients 
including later progression to epilepsy, cognitive impairment, and death. Mortality during 
or after SE remains a severe, but common outcome with estimates of 30% mortality in 
adults.13,21 In a meta-analysis by Lv and colleagues, the overall mortality rate for SE was 
considerably lower than 30%, but the authors noted a 33% mortality rate in studies and 
included analysis of RSE. Additionally, they found that etiology and age can also be a 
predictor of mortality.22 Pediatric SE patients have a much lower risk of death (3-5%) 
compared to elderly patients (25-31%).22-26 
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One of the most significant outcomes of seizures, and especially SE, is the risk of 
recurrent seizures. The phenomenon that “seizures beget seizures” has been observed 
since the 1800’s when Sir William Gowers noted that patients who have at least two 
seizures are more likely to have future seizures and as the time between seizure events 
decreases, the less likely it becomes for a patient to stop having seizures.27 Indeed, the 
risk of experiencing further seizures in epilepsy patients and when to diagnose a patient 
with epilepsy after a first seizure is currently an area of research and debate.28-30 After SE, 
the risk of developing further seizures is considerable with about 40% of adults developing 
epilepsy within 10 years after an SE event.31 In pediatric populations, the reported risk of 
developing epilepsy is highly variable depending on study design and duration of follow 
up.24 The incidence of pediatric patients developing epilepsy with SE as the second 
seizure event for diagnosis ranges from 10.5-82% over 10 years.24,32,33 The clinical 
observation that seizures beget seizures is well documented, but the pathophysiology 
behind this phenomenon is still poorly understood and may be related to changes to the 
blood-brain barrier.  
 
1.3 Blood-Brain Barrier Background 
The blood-brain barrier is composed of a continuous capillary network of 
endothelial cells and serves as a selective interface between the cerebrovasculature 
(Figure 1) and the brain parenchyma. Paul Ehrlich first made the observation that the 
CNS was different than other organ systems in that the brain and spinal cord were not 
stained by intravenous (i.v.) injected dyes, but the term blood-brain barrier was not coined 
until later by Max Lewandowski when he noted that the brain was sheltered of 
pharmacologic effects from i.v. administration of bile acids.34,35 Ehrlich’s student, Edwin 
Goldman, later demonstrated that intraventricular administration of Trypan blue stained 
only brain tissue: concluding that the brain was a protected compartment from the blood.36  
This early work was expanded in a significant way with the advent of the electron 
microscope. With this new technology, Reese, Karnovsky, and Brightman were able to 
show that tight junctions in brain capillaries exclude paracellular transport of tracer 
molecules such as horse radish peroxidase (MW 40,000 Da) and lanthanum (MW 139) 
from passing into the brain parenchyma.37,38 Tight junctions are complex protein structures 
that include transmembrane proteins such as zona occludens, claudins, and junction 
adhesion molecules which seal the space between endothelial cells to form an anatomical 
barrier which prevents sanguineous materials from entering the brain and vice versa.39,40 
Dysfunction and leakage of the blood-brain barrier has been implicated in pathologies of 
numerous disease states such as stroke, Alzheimer’s disease, amyotrophic lateral 
sclerosis, multiple sclerosis, and epilepsy.41-46 
 
Figure 1: Latex Mold of 
Cerebrovasculature. Adopted for use 
with license agreement from Oxford 
University Press.1 
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1.4 Clinical Association Between Blood-Brain Barrier Opening and Seizures 
There is a variety of clinical evidence to support the association between seizures and 
blood-brain barrier opening. The blood-brain barrier normally excludes sanguineous 
proteins such as albumin from the brain. However, albumin extravasation has been seen 
by immunohistochemistry in resected tissue from temporal lobe epilepsy patients with 
complex partial seizures and patients with secondary generalized seizures.47 Of note, 
profoundly more extravasation was observed in PWEs who died during SE. In patients 
with primary CNS lymphomas, one developing treatment option is to undergo blood-brain 
barrier disruption with hyperosmotic mannitol.48 Focal seizures are a common side effect 
of this treatment with 33.6% of patients having seizure activity despite prophylactic 
treatment with anti-seizure drugs.49 Sera from these patients also have significantly 
elevated S100β levels. S100β is also being investigated as a marker of blood-brain barrier 
leakage and as a prognostic marker after sports-related concussions and traumatic brain 
injury.50-54 Clinical seizures are seen in 12% of patients with severe traumatic brain injury 
and early seizure prophylaxis with phenytoin or levetiracetum is common.55 There is a 
clear association between breakdown of the blood-brain barrier and seizures, but the 
mechanisms which regulate blood-brain barrier leakage and treatment strategies are still 
in need of investigation.  
 
1.5 Mechanism of Blood-Brain Barrier Leakage in Epilepsy 
Data from animal experiments have shown that blood-brain barrier opening can 
lead to epileptogenesis.56,57 Additionally, findings from studies show blood-brain barrier 
leakage after the development of seizures.48,58 These observations support the clinically 
held canon that “seizures beget seizures” and the underlying molecular mechanisms and 
pharmacologic targets of blood-brain barrier leakage in epilepsy are central to this thesis. 
Glutamate is the primary excitatory neurotransmitter in the brain and is released in 
large amounts during seizure activity.59,60 After seizure-induced release, glutamate causes 
changes at the blood-brain barrier such as increased P-glycoprotein (P-gp) expression.61 
This effect is mediated by glutamate through a signaling pathway involving N-methyl-D-
aspartate receptor (NMDAR) on brain capillaries, arachidonic acid, and the 
cyclooxygenase-2 (COX-2) enzyme.62,63  
Exposing isolated rat brain capillaries ex vivo to glutamate increased MMP protein 
expression and activity, decreased TJ protein expression, and increased capillary 
leakage.64 Similar changes were observed in a status epilepticus rat model. These effects 
were abolished with inhibitors of cytosolic phospholipase A2 (cPLA2). Additionally, these 
effects were absent when brain capillaries isolated from cPLA2 knock-out mice were 
exposed to glutamate.64 Given what is known about the connection between P-gp and the 
glutamate-arachidonic acid-COX-2 pathway, taken together with unpublished cPLA2 data, 
we conclude blood-brain barrier leakage to be a result of the same pathway. Further 
unpublished ex vivo data from this laboratory suggest that upregulation of MMPs, 
degradation of TJs, and barrier leakage are also mediated by the NMDAR, cPLA2, 
arachidonic acid, and COX-2. However, preliminary data also suggest inhibition of COX-
2 alone is insufficient to prevent these changes. Indeed, inhibition of 5-lipoxygenase (5-
LOX) in addition to COX-2 inhibition ameliorated the upregulation of MMPs, TJ 
degradation, and barrier leakage suggesting that both enzymes are involved in causing 
barrier leakage. Thus, we propose a positive feedback loop in which glutamate released 
during seizures acts on capillary NMDA receptors to cause blood-brain barrier disruption 
through cPLA2, COX-2 and 5-LOX leading to increased MMP expression, degradation of 
TJs and increased barrier leakage which increases the likelihood of further seizures 
(Figure 2). While the mechanisms behind barrier leakage have been thoroughly 
investigated in isolated brain capillaries ex vivo by our laboratory, the next logical step is 
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to confirm biological relevance of this pathway by pharmacologic prevention of barrier 
leakage in vivo. We hypothesize that seizures trigger LOX and COX mediated blood-brain 
barrier leakage and that dual LOX/COX inhibition prevents barrier leakage in an in vivo 
status epilepticus model.  
 
2. Methods  
 
2.1 Chemicals, Equipment and Materials 
 
Table 2.1.1: Chemicals 
Item Use Manufacturer 
Item 
Number Lot(s) 
Dulbecco's 
Phosphate 
Buffered 
Saline w/ Ca++ 
and Mg++ 
Capillary 
Isolation 
GE Healthcare Life 
Sciences (Logan, UT) 
SH30264.
01 
AC10538277, 
AB216610 
Glucose 
Capillary 
Isolation 
Millipore Sigma, 
Burlingon, MA, USA 
G7528-
250G 037K01901 
Sodium 
Pyruvate 
Capillary 
Isolation 
Millipore Sigma, 
Burlingon, MA, USA 
P2256-
25G SLBP4879V 
Ficoll® PM 
400 
Capillary 
Isolation 
Millipore Sigma, 
Burlingon, MA, USA 
F4375-
500G SLBN3686V 
Bovine Serum 
Albumin 2M 
Capillary 
Isolation 
Millipore Sigma, 
Burlingon, MA, USA 
A9647-
100G SLBR6769Vd 
Sterile Normal 
Saline Solution 
Injection 
Formulation 
Henry Schein (Dublin, 
OH) 
NDC 
50989-
641-16 B1704082 
Dextrose 
Solution 50% 
Injection 
Formulation 
Henry Schein (Dublin, 
OH) 002460 A1610091 
Figure 2: Proposed Positive Feedback Loop for Epileptogenesis. A positive 
feedback loop in which glutamate released during seizures propagates further seizures 
by glutamate acting on capillary NMDA receptors to cause blood-brain barrier 
disruption through COX-2 and 5-LOX which increase MMP expression, degradation of 
TJs to increase barrier leakage which increases the likelihood of further seizures. 
 
5 
Table 2.1.1 (Continued) 
Licofelone  
Injection 
Formulation 
Santa-Cruz, Dallas, 
TX; Toronto Research 
Chemicals 
SC-
207826; 
L397730 
A1912, J1317; 
7-MAK-90-1 
Zileuton 
Injection 
Formulation Cayman Chemicals,  10006967 0490336-18 
Celecoxib 
Injection 
Formulation 
Selleckchem, Houston, 
TX S1261 S126104 
Scopolamine 
Methylbromide 
Injection 
Formulation 
Millipore Sigma, 
Burlingon, MA, USA S8502-1G SLBL9646V 
Lithium 
Chloride 
Injection 
Formulation 
Millipore Sigma, 
Burlingon, MA, USA 
L4408-
100G SLBP9949V 
Pilocarpine 
HCL 
Injection 
Formulation 
Millipore Sigma, 
Burlingon, MA, USA 
P6503-
10G 
MKBZ8075V, 
MKBW5175V 
Tween 80 
Injection 
Formulation 
Millipore Sigma, 
Burlingon, MA, USA 
P1754-
500ML MKBR2340V 
PEG 200 
Injection 
Formulation 
Millipore Sigma, 
Burlingon, MA, USA 
P3015-
250G MKBR7821V 
Texas Red™ 
TR Leakage 
Assay 
Sigma, St. Louis, MO, 
USA S3388 068K3799V 
D-Mannitol 
TR Leakage 
Assay 
Sigma, St. Louis, MO, 
USA M4125 099K0007 
Complete 
Protease 
Inhibitor 
Tablets 
Membrane 
Fraction 
Isolation 
Roche Diagnostics 
GmBH, Mannheim, 
Germany 
11697498
001 10659100 
1X Phosphate 
Buffered 
Saline (PBS) 
w/o Ca2+ and 
Mg2+ 
Membrane 
Fraction 
Isolation 
GE Healthcare Life 
Sciences (Logan, UT) 
SH30256.
01 
AC10237763, 
AC10260338 
CellLytic MT 
Cell Lysis 
Reagent 
Membrane 
Fraction 
Isolation 
Millipore Sigma, 
Burlingon, MA, USA     
NaOH 
PH 
Adjustment Fluka Analytical 71474-1L BCBM3206V 
HCl 1N 
PH 
Adjustment Fisher Chemical SA48-500 161478 
Human S100β 
ELISA Kit 
S100β 
ELISA 
Millipore Sigma, 
Burlingon, MA, USA 
EZHS100
B-33K 2985955, 
Protease 
Inhibitor 
S100β 
ELISA 
Millipore Sigma, 
Burlingon, MA, USA 
539131-
10VL D00173716 
Baby Food 
Animal 
Recovery 
Beech-Nut Nutrition 
Co., Amsterdam, NY, 
USA 
Apple and 
Pear 
Flavored  
Rodent critical  
Care Diet – 
Professional 
Line 
Animal 
Recovery Oxbow Animal Health N/a 163546r 
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Table 2.1.2:  Equipment and Key Materials 
Item Manufacturer Use 
Sorvall™ Legend™ XTR 
Tabletop centrifuge 
Sorvall, ThermoFisher 
Scientific,  Capillary Isolation 
50 ml Potter-Elvehjem tissue 
grinder (Clearance 150-230 
um) 
Thomas Scientific, 
Swedesboro, NJ, USA Capillary Isolation 
15 ml Dounce Homogenizer 
(Clearance: 80-130 uM) VWR, Radnor, PA, USA Capillary Isolation 
S6 E Greenough 
Stereomicroscope 
Leica Microsystems, 
Wetzlar, Germany Capillary Isolation 
Dumont #5 Forceps 
Fine Science Tools, 
Heidelberg, Germany Capillary Isolation 
RZR 2102 Control Electronic 
Stirrer 
Heidolph, Schwabach, 
Germany Capillary Isolation 
300 um filter mesh Spectrum Laboratories Capillary Isolation 
pluristrainer® Filters (pore 
size 30 um) PluriSelect Capillary Isolation 
15 ml  Falcon® tube 
Corning™, Corning, NY, 
USA Capillary Isolation 
50 ml Falcon® tube 
Corning™, Corning, NY, 
USA Capillary Isolation 
Axiovert 25 Inverted Phase 
Contrast Microscope 
Zeiss, Oberkochen, 
Germany Capillary Isolation 
Fiberlite™ F15-8x50cy 25 
degree fixed angle rotor 
ThermoFisher Scientific, 
Waltham, MA, USA Capillary Isolation 
TX-750 Swinging Bucket 
Rotor 
ThermoFisher Scientific, 
Waltham, MA, USA Capillary Isolation 
Millex® GV 0.22 um filter 
unit Millpore Sigma Capillary Isolation 
50 ml Centrifugation tube 
ThermoFisher Scientific, 
Waltham, MA, USA Capillary Isolation 
accuSpin Micro 17R fixed 
angle microcentrifuge 
Fischer Scientific, 
Pittsburgh, PA ELISA 
Synergy H1 Plate Reader 
BioTek, Winooski, VT, 
USA ELISA 
Gen5™ Software 
BioTek, Winooski, VT, 
USA ELISA 
Polytron™ PT 2500 E 
Ultraspeed Homogenizer 
Kinematica, Luzern, 
Switzerland 
Membrane Fraction 
Isolation 
3.5 ml Ultracentrifuge tubes 
Beckman Coulter, Brea, 
CA, USA 
Membrane Fraction 
Isolation 
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Table 2.1.2 (Continued) 
TLA 100.3 Fixed angle 30 
degree Ultracentrifuge Rotor 
Beckman Coulter, Brea, 
CA, USA 
Membrane Fraction 
Isolation 
Optima TLX Ultracentrifuge 
Beckman Coulter, Brea, 
CA, USA 
Membrane Fraction 
Isolation 
2 mm micro stir bar 
VWR International, 
Radnor, PA 
Membrane Fraction 
Isolation 
Marathon 3200R swing-head 
centrifuge 
Fischer Scientific, 
Pittsburgh, PA Rat Serum Isolation 
3.5 ml SST Vacutainer 
Becton Dickinson, Franklin 
Lakes, NJ Rat Serum Isolation 
Smart2Pure DI water filter  Thermo Scientific ELISA 
Leica TCS SP5 Confocal 
Microscope  
Leica Instruments, Ewtzlar, 
Germany  TR Leakage Assay 
Image J Software v. 1.48v 
Wayne Rasband, NIH, 
USA Data Analysis 
GraphPad Prism 7  
GraphPad, San Diego, CA, 
USA Data Analysis 
 
2.2 Buffers 
 
Table 2.2.1:  Phosphate Buffered Saline without Ca++ or Mg++ 
Additive mg/L mmol/L 
KH2PO4 (Anhydrous) 144 1.06 
NaCl 9000 154.0041 
Na2HPO4 795 5.6002 
 
Table 2.2.2: Isolation Buffer: DPBS with Ca++, Mg++, Glucose, and Pyruvate  
(pH 7.4)  
Additive mg/L mmol/L 
CaCl 100 0.9 
KCl 200 2.7 
KH2PO4 (Anhydrous) 200 1.47 
MgCl-6H2O 100 0.49 
NaCl 8000 136.9 
Na2HPO4 1150 8.1 
D-Glucose 900.8 5 
Sodium Pyruvate 110 1 
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Table 2.2.3: BSA Buffer: 1% BSA in DPBS with Ca++, Mg++, Glucose, and Pyruvate  
(pH 7.4) 
Additive mg/L mmol/L 
CaCl 100 0.9 
KCl 200 2.7 
KH2PO4 (Anhydrous) 200 1.47 
MgCl-6H2O 100 0.49 
NaCl 8000 136.9 
Na2HPO4 1150 8.1 
D-Glucose 900.8 5 
Sodium Pyruvate 110 1 
Bovine Serum Albumin 10000  
 
Table 2.2.4: Lysis Buffer 
Additive Quantity Required Concentration 
50x Complete Protease 
Inhibitor Solution 
500 μl 9.1% (4.55x) 
CellLytic™ MT Lysis Reagent 5 ml 90.9% 
Total 5.5 ml  
 
Table 2.2.5: LPC Buffer  
Additive Quantity Required Concentration 
Complete Protease Inhibitor 1 tablet 10x 
CellLytic™ MT Lysis Reagent 5 ml 50% 
PBS w/o Ca++ or Mg++ 5 ml 50% 
Total 10 ml  
 
2.3 Injection Formulations 
 
Table 2.3.1: Vehicle 
Additive Quantity Required % Volume 
PEG 200 5 ml 5% 
Tween 80 1 ml 1% 
Normal Sodium Saline 94 ml 94% 
Total 100 ml  
 
Table 2.3.2: Licofelone 
Additive Quantity Required Concentration 
LCF 40 or 80 mg 2 or 4 mg/ml 
PEG 200 1 ml 5% 
Tween 80 200 µl 1% 
Normal Sodium Saline 18.8 ml 94% 
Total 20 ml  
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Table 2.3.3: Zileuton and Celecoxib 
Additive Quantity Required Concentration 
Zileuton 40 mg 2 mg/ml 
Celexoxib 80 mg 4 mg/ml 
PEG 200 1 ml 5% 
Tween 80 200 µl 1% 
Normal Sodium Saline 18.8 ml 94% 
Total 20 ml  
 
2.4 Animal Housing and Handling 
Female Wistar rats (10 weeks of age, 180-220 g) were purchased from Charles 
River Laboratories (Portage, MI), housed under standard conditions of 23º C, 35% relative 
humidity, 12-hour light/dark cycle and allowed access to water and standard rodent diet 
ad libitum (Harlan Tecklad Chow 2918, Harlan Laboratories Inc., Indianapolis, IN,). Each 
rat was handled for 1-2 minutes daily for a minimum of 3 days prior to any experiment. All 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) 
at the University of Kentucky protocol #2014-1234 (PI: Bauer). 
 
2.5 Pilocarpine Status Epilepticus Induction in Rats 
SE was induced using a modified lithium chloride and pilocarpine model.65-67 Rats 
were pre-treated with lithium chloride (127 mg/kg, i.p.) 12 to 15 hours before the first 
pilocarpine dose and with scopolamine methylbromide (1 mg/kg, i.p.) 30 minutes before 
the first pilocarpine administration. SE was induced in rats by administration of the 
muscarinic agonist pilocarpine HCl every 20 minutes. SE was induced by an i.p. bolus of 
30 mg/kg pilocarpine was given for the first dose followed by 10 mg/kg i.p doses thereafter 
until SE was achieved. All seizures during the induction of SE were scored based on 
Racine’s scale68 and SE was defined by continuous tonic-clonic seizures or intermittent 
class 4 and 5 seizures without recovery of normal conscious behavior in between. SE was 
terminated after 90 minutes by i.p. administration of 10 mg/kg diazepam every 20 minutes 
until cessation of visible seizures. Rats that received pilocarpine but did not enter SE 
served as a control group (pilocarpine control, pilo) to ensure that observations made of 
the SE group are due to seizure activity during 90 minutes of SE and not pharmacologic 
effects of pilocarpine. The negative control rats received LiCl, scopolamine 
methylbromide, diazepam, and normal saline in place of pilocarpine. 
After SE termination with diazepam, rats were given 3-5 ml 5% dextrose in normal 
saline (D5NS) by s.c. administration. For experiments in which rats were euthanized 24 
or 48 hours after SE cessation, D5NS was also administered in the evening after the 
induction and the following morning. Rats were closely monitored until euthanasia and 
additional doses of diazepam were given when seizure activity was observed. Recovering 
rats were fed apple sauce, rodent intensive care diet, and softened rodent chow until the 
animals were able to resume normal feeding behavior.  
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2.6 Time Course Design 
Five SE inductions were conducted as previously described and serum was collected at 
three time points: immediately following SE termination (n = 2 experiments), 24 hours after 
SE termination (n = 1 experiment), and 48 hours after SE (n = 2 experiments) (Figure 3). 
These samples were used to determine at which time point S100β would be most 
consistently elevated.  
  
 
 
2.7 Licofelone Study Design 
Rats underwent SE induction as described above. In addition, rats were dosed i.p. 
with either vehicle or the dual LOX and COX inhibitor licofelone (LCF).69 This study was 
divided into two experiments using 5 mg/kg and 10 mg/kg licofelone.70 LCF or vehicle was 
given every 12 hours starting 2 days before the induction (Figure 4). In each experiment, 
this produced 4 groups of animals, in addition to a control group, defined by whether they 
received vehicle or LCF and whether or not they developed SE (Pilo-Veh, Pilo-LCF, SE-
Veh, SE-LCF).  
 
 
 
  
Figure 4. Timeline for Licofelone Experiments. The timeline is centered on the time 
of the first pilocarpine injection with interventions labeled at Time 0 ± hours. Sera were 
collected 48 hours after SE termination and used to measure S100β levels. 
 
Figure 3: Blood-Brain Barrier Leakage Time Course. At three time points, serum 
samples were collected to measure S100β concentrations after SE.  
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2.8 Zileuton & Celecoxib Study Design 
Rats underwent SE induction as described above. In addition, rats were dosed i.p. 
with either vehicle or the 5-LOX inhibitor zileuton (5 mg/kg) and the COX-2 inhibitor 
celecoxib (10 mg/kg) (ZC). ZC or vehicle was given every 12 hours starting 2 days before 
the induction. (Figure 5). In each experiment, this produced 4 groups of animals, in 
addition to a control group, defined by whether they received vehicle or LCF and whether 
or not they developed SE (Pilo-Veh, Pilo-ZC, SE-Veh, SE-ZC). 
 
 
  
2.9 Rat Serum Isolation 
 Rats were euthanized by CO2 inhalation 0, 24, or 48 hours after SE termination. 
The thoracic cavity was opened and blood was drawn via right ventricular heart puncture. 
This blood was collected in a 3.5 ml SST vacutainer carefully inverted 5 times and 
incubated at room temperature for 30 minutes. The tubes were centrifuged at 1,300 g for 
10 minutes at 4 ⁰C in a swing-head centrifuge. Serum samples were taken as aliquots of 
the supernatant and kept for short term storage at -20 ⁰C until use. 
 
2.10 S100β ELISA 
ELISA reagents and standards as well as serum samples were prepared and 
plated as recommended in the manufacturer’s protocol (Kit # EZHS100B-33K, 
MilliporeSigma, Burlington, MA). The reaction product was measured by absorbance at 
450 nm using a Synergy H1 plate reader and corrected with a reference absorbance at 
590 nm. The absorbance was compared against a standard curve to calculate the 
concentration of S100β.  
 
2.11 Capillary Isolation 
Rats were euthanized by CO2 inhalation and decapitated. Brains were collected in 
ice-cold isolation buffer. Using a stereo microscope, the meninges, choroid plexus, brain 
stem, and white matter were removed with Dumont #5 forceps and the remaining cortical 
tissue was minced with a scalpel. This tissue underwent two homogenization steps. In the 
first homogenization, the minced tissue and 3 ml of isolation buffer per rat brain was added 
to a 50 ml Potter-Elvehjem homogenizer (clearance: 150-230 µm). 100 up-and-down 
strokes were used to homogenize the tissue using an overhead stirrer set to 50 rpm. Then, 
the homogenate was transferred to a Dounce homogenizer (clearance: 25-75 µm) and 
homogenized further with 20 strokes. The homogenate was then divided equally into two 
centrifugation tubes and 2.5 ml of 30% Ficoll® per rat brain plus 0.5 ml of isolation buffer 
per rat brain were added to each tube. The homogenates were separated by density 
Figure 5. Timeline for Zileuton + Celecoxib Experiments. The timeline is centered 
on the time of the first pilocarpine injection with interventions labeled at Time 0 ± hours. 
Sera were collected 48 hours after SE termination and used to measure S100β levels 
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centrifugation at 5,800 g for 15 min at 4 ⁰C in a 45⁰ fixed-angle rotor. The supernatant was 
discarded and the pellet containing capillaries, red blood cells, and other cellular debris 
was resuspended in BSA buffer and filtered through a 300 µm mesh to remove larger 
vessels and brain debris. The filtrate was passed through a 30 µm pluriStrainer® after 
which the majority of capillaries remained on top of the filter.64 The filtrate was passed 
through another 30 µm pluriStrainer® to minimize capillary loss. The capillaries were 
washed off of each filter by inverting it over a 50 ml Falcon tube and rinsing it with 50 ml 
BSA buffer. These tubes were centrifuged at 1,500 g for 3 min at 4 ⁰C and the pellet 
(Figure 6) was resuspended in isolation buffer and transferred to a 15 ml conical tube and 
filled to 15 ml with isolation buffer. After another centrifugation at 1,500 g for 3 min at 4 ⁰C 
and washing, capillaries were either used for ex vivo Texas Red™ leakage assays or for 
capillary membrane isolations.  
2.12 Capillary Membrane Fraction Isolation  
Capillaries suspended in isolation buffer were centrifuged at 4,700 g for 1 min at 4 
⁰C and the supernatant was discarded. The pellets were resuspended in lysis buffer and 
transferred into ultracentrifuge tubes. Capillaries were homogenized for 3 min 20 seconds 
using an ultraspeed homogenizer at 30,000 RPM. The crude membrane fraction was 
isolated by differential centrifugation. First, the homogenates were centrifuged at 30,000 
RPM (38,203 x g) for 30 min at 4 ⁰C. The supernatant containing the cellular membrane 
fraction was transferred in a new set of centrifugation tubes using a Pasteur pipet and 
centrifuged again at 95,000 RPM (383,093 x g) for 2 hours at 4 ⁰C; the remaining pellet 
containing cell debris and other cellular organelles was discarded. The resulting pellets 
(Figure 7, crude membrane fraction) were resuspended in LPC buffer, transferred to 
microcentrifuge tubes and stored at -80 ⁰C.  
 
  
Figure 7: Isolated membrane 
fraction of rat brain capillaries. 
Representative image of 
membrane fractions pellets. 
These isolates will be used to 
determine capillary membrane 
protein concentrations. 
Figure 6: Isolated rat brain ca-
pillary pellets. A representative 
image of the capillary pellet size. 
These capillaries are resus-
pended for confocal microscopy 
and for isolation of capillary 
membrane fractions. 
13 
2.13 Texas Red™ Leakage Assay 
Texas Red™ (TR) leakage assays were performed as previously described.71,72 TR is a 
fluorescent organic anion (MW 625 Da, excitation wavelength 543 nm, emission 
wavelength 615 nm) and is actively transported into the lumen of brain capillaries. When 
isolated brain capillaries are incubated in solution with TR for 1 hour, the fluorescent 
molecule accumulates in the lumen of the capillaries and can be quantified using confocal 
microscopy (Figure 8) and image analysis software. Confocal microscope setting were as 
follows: 63.0x1.2 D-water UV objective, pinhole: 111.4 µm, zoom: 4, image format: 
512x512, scanning speed: 400 Hz, line average: 1, frame average: 3, laser: 543 HeNe. If 
the brain capillaries are leaky, TR leaks out of the lumen, and thus, luminal TR 
fluorescence decreases over time. Assuming first order elimination kinetics, this 
information can be used to calculate a leakage rate using non-linear regression analysis.  
 
 
2.14 Statistical Analysis 
Statistical analysis was conducted using GraphPad Prism 7 and results were considered 
significant when p<0.05. Significance reported as: * p<.05; ** p<0.01; *** p<0.001; **** 
p<0.0001. Results for post-SE S100β ELISAs and Texas Red leakage assays were 
assessed using one-way analysis of variance (ANOVA) with Tukey’s test for post-hoc 
analysis of comparisons between groups.  
 
3. Results 
 
3.1 Detection of Serum S100β by ELISA 
Data from previous experiments with isolated capillaries from SE rats suggest that 
blood-brain barrier leakage occurs 48 hours after SE. To determine if this observation 
could be corroborated by detection of brain derived protein leaking into the blood, ELISA 
analysis for serum S100β was performed. S100β is an astrocyte-derived neurotrophic 
protein not normally found in the blood unless barrier leakage is present.73 Rat serum 
samples were analyzed in duplicate by ELISA to determine S100β concentration. A time 
course was conducted (Figure 3) and serum S100β concentrations were measured at 0, 
24, and 48 hours after SE. While some SE rats exhibited highly elevated S100β levels 
immediately after SE compared to control rats or pilocarpine control rats (received 
pilocarpine but did not develop SE), the effect was inconsistent (Figure 9) (SD=189 
pg/ml). More specifically, the data seemed to divide into two groups: one group with S100β 
levels comparable to controls and one group which had distinctly elevated S100β.  
Figure 8: TR Capillary Leakage 
A: Control capillary loaded with 2 μM Texas Red 
at time point 0 min 
B: Control capillary after removal of Texas Red at 
time point 60 min 
C: Capillary treated with Mannitol with after 
removal of Texas red at time point 60 min 
A B C 
5 µm 
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At 24 hours after SE, no increase in S100β was observed compared to controls 
(Figure 10). Conversely, serum S100β was reproducibly and significantly increased in SE 
rats at 48 hours after SE (Figure 11). These data corroborate preliminary data showing 
barrier opening at 48 hours after SE and support serum S100β concentration as a 
surrogate marker for barrier leakage. 
 
Figure 9. Serum S100β Levels 
Immediately Following SE. Serum 
S100β concentrations were non-
significantly elevated for SE rats 
compared to controls and compared to 
rats that received pilocarpine but did not 
develop SE. S100β concentrations 
measured as pg/ml; data are mean ± 
SEM (n = 2 independent experiments); 
group sizes: Control n = 10; Pilo n = 8; SE 
n = 28. Statistical comparison: ns, 
p=0.139; ANOVA.  
Figure 10. Serum S100β levels 24 
Hours After SE. Serum S100β 
concentrations were similar to those in 
SE rats compared to controls and 
compared to rats that received 
pilocarpine but did not achieve SE. 
S100β concentrations measured as 
pg/ml; data are mean ± SEM; Group 
sizes: Control n = 4; Pilo n = 4; SE n = 
12. Statistical comparison: ns, 
p=0.4316; ANOVA. 
Figure 11. Serum S100β Levels 48 
Hours after SE. In pooled data from 
two 48 hour SE inductions, serum 
S100β concentrations were 
significantly elevated for vehicle 
treated SE rats compared to controls 
and compared to rats that received 
pilocarpine but did not achieve SE. 
S100β concentrations measured as 
pg/ml; data are mean ± SEM (n=2 
independent experiments); group 
sizes: Control n = 9; Pilo n = 10; SE n 
= 12. Statistical comparison: **, Control 
vs SE, p<0.01; ***, Pilo vs SE, 
p<0.001; ANOVA with Tukey’s post-
hoc analysis. 
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3.2 Prevention of Blood-Brain Barrier Leakage with Licofelone 
Since the astrocyte-derived protein S100β is consistently elevated in the serum of 
SE rats at 48 hours after SE and preliminary ex vivo data suggest leakage in brain 
capillaries is mediated by 5-LOX and COX-2, an in vivo study was conducted to determine 
if inhibition of LOX and COX would prevent S100β elevation after SE. First, rats were 
dosed with either vehicle or the dual LOX and COX inhibitor licofelone (5 mg/kg, i.p. 
injection) every 12 hours for 7 doses beginning 2 days before the SE induction. Serum 
and brain capillaries were isolated from rats after 48 hours. Serum S100β was measured 
by ELISA (Figure 12). Rats from the vehicle and LCF groups that received pilocarpine, 
but did not develop SE had similar S100β serum levels as the negative controls (61, 73, 
75 pg/ml, respectively, p > 0.99 for all). Vehicle-dosed rats that developed SE had a 4.8-
fold increase in mean S100β serum levels compared to control rats (p < 0.05). Similarly, 
LCF-dosed rats that developed SE had increased mean S100β levels and were 
significantly greater than controls (p < 0.05), but appeared to be divided into two sub-
groups: one group with concentrations similar to the SE-Veh group and one with 
concentrations similar to controls.  
To assess if LCF treatment could prevent leakage in capillaries isolated from SE 
rats, confocal microscopy was used to measure the leakage rate of fluorescent Texas 
Red™ (Figure 13). TR leakage rates for capillaries of the SE-Veh group equaled that of 
the assay positive control (capillaries incubated in 100 mM, hyperosmotic mannitol). 
Conversely, isolated capillaries from the vehicle- and LCF-dosed rats that received 
pilocarpine but did not develop SE had leakage rates that were equal to those in negative 
control capillaries. Brain capillaries from LCF-treated SE rats had lower leakage rates than 
those from SE-vehicle rats, but did not decrease to control levels.  
Based on these observations, the experiment was repeated with 10 mg/kg LCF 
(Figure 14). Serum S100β was measured by ELISA. Rats from the vehicle and LCF 
groups that received pilocarpine, but never developed SE, had similar S100β serum 
concentrations as the negative controls. Vehicle-dosed rats that developed SE had an 8.4-
fold increase in S100β concentration compared to controls (p<0.0001). In contrast to the 
previous experiment, LCF-dosed rats that developed SE had significantly lower S100β 
serum concentrations than SE-Veh rats and were consistent with those of the control and 
pilocarpine group rats (SE-Veh vs SE-LCF: p < 0.0001;  Control vs SE-LCF: p > 0.99; Pilo-
LCF vs SE-LCF: p=0.92). 
To assess if the increased LCF dose would also prevent leakage in capillaries 
isolated from SE rats, confocal microscopy was used to measure the leakage rate of 
fluorescent Texas Red™ (Figure 15). TR leakage rates for capillaries of the SE-Veh group 
() were similar to those of the positive control (SE-Veh: 0.7± 0.23 min-1; 100 mM mannitol: 
0.8±0.27 min-1). Conversely, isolated capillaries from the Pilo-Veh, Pilo-LCF and SE-LCF 
had leakage rates equal to negative control capillaries (Control: 0.2±0.04 min-1 Pilo-Veh: 
0.2±0.05 min-1; Pilo-LCF: 0.2±0.07 min-1; SE-LCF: 0.2±0.03). Put together with decreased 
serum S100β in LCF treated SE rats, these data suggest licofelone prevents SE induced 
blood-brain barrier leakage in a dose-dependent manner (Figure 16).  
 
 
16 
 
Figure 13: 5 mg/kg Licofelone Decreases Barrier Leakage in Brain Capillaries. 
The rate of Texas Red™ leakage from capillaries isolated from LCF-treated SE rats was 
decreased in comparison to vehicle treated SE rats. However, the leakage rate was 
not decreased to control levels. Luminal TR measured as arbitrary fluorescence units 
and first-order efflux rates were calculated by non-linear regression. Efflux rates are 
shown as mean ± SEM for n = 7 capillaries per time point for each group; group sizes: 
Ctrl n = 6; Pilo-Veh n = 2, Pilo-LCF n = 3, SE-Veh n = 8, SE-LCF n = 8. 
Figure 12: 5 mg/kg Licofelone Does Not Prevent S100β Leakage After SE 
Serum S100β concentrations were elevated for vehicle-treated SE rats compared to 
controls and compared to rats that received pilocarpine but did not achieve SE. SE 
rats which received LCF also had elevated serum S100β levels on average, but had 
large variability (SD = 195 pg/ml). S100β concentrations measured as pg/ml; data are 
mean ± SEM; group sizes: Ctrl n = 6; Pilo-Veh n = 2, Pilo-LCF n = 3, SE-Veh n = 8, 
SE-LCF n = 8. Statistical comparison: *, Control vs SE-Veh, p<0.05; *, Control vs SE-
LCF, p<0.05; ANOVA with Tukey’s post-hoc analysis.  
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Figure 14. 10 mg/kg licofelone prevents S100β leakage after status epilepticus. 
Serum S100β concentrations were elevated for vehicle-treated SE rats compared to 
controls and compared to rats that received pilocarpine but did not develop SE. Rats 
treated with LCF had significantly lower levels of serum S100β compared to SE rats 
which received vehicle (p < 0.0001). S100β concentrations measured as pg/ml; data 
are mean ± SEM; group sizes: Ctrl n = 6; Pilo-Veh n = 6, Pilo-LCF n = 7, SE-Veh n = 
8, SE-LCF n = 7. Statistical comparison: ****, Control vs SE-Veh, p<0.0001; ****, SE-
Veh vs SE-LCF; ns, Control vs SE-LCF, p>0.99; ANOVA with Tukey’s post-hoc 
analysis. 
Figure 15: 10 mg/kg Licofelone Decreases Barrier Leakage in Brain Capillaries. 
The rate of Texas Red™ leakage from capillaries isolated from LCF treated SE rats was 
decreased to control levels. Luminal TR measured as arbitrary fluorescence units and 
first-order efflux rates were calculated by non-linear regression. Efflux rates are shown 
as mean ± SEM for n = 7 capillaries per time point for each group; group sizes: Ctrl 6; 
Pilo-Veh n = 6, Pilo-LCF n = 7, SE-Veh n = 8, SE-LCF n = 7. 
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3.3 Prevention of Blood-Brain Barrier Leakage with Zileuton and Celecoxib 
Licofelone has been used in some clinical trials, but it has not been FDA 
approved.73,74 Additionally, it lacks COX-2 selectivity and preliminary data suggest this 
pathway is mediated by COX-2 and not COX-1.69 Therefore, rats were dosed with either 
vehicle or the 5-LOX inhibitor zleuton (5 mg/kg, i.p. injection) and the COX-2 inhibitor 
celecoxib (10 mg/kg, i.p. injection) every 12 hours for 7 doses beginning 2 days before the 
SE induction. Serum and brain capillaries were isolated from the rats 48 hours after SE. 
Serum S100β was measured by ELISA (Figure 17). Pilo-Veh and Pilo-ZC rats had similar 
S100β concentrations (51 pg/ml and 49 pg/ml, respectively) as the negative controls (36 
pg/ml). Vehicle-dosed rats that developed SE had 11.2-fold increase in mean S100β 
concentration compared to controls (p < 0.0001). SE-ZC rats had significantly lower S100β 
concentrations than SE-Veh (p < 0.0001) and were consistent with that of the control and 
pilocarpine groups (Control vs SE-ZC: p>0.99; Pilo-Veh vs SE-ZC: p>0.99; Pilo-ZC vs SE-
ZC: p>0.99). 
  
Figure 16: Licofelone Study Dose Response. Licofelone dosing with 10 mg/kg 
significantly decreased S100β concentrations compared to SE-Veh and SE-LCF (5 
mg/kg). Data are pooled (†) from 2 independent experiments for Ctrl, Pilo-Veh, and 
SE-Veh groups. S100β concentrations measured as pg/ml; data are mean ± SEM; 
group sizes: Ctrl† n = 12; Pilo-Veh† n = 8, Pilo-LCF (5 mg/kg) n = 3, Pilo-LCF (10 mg/kg) 
n = 7, SE-Veh† n = 16, SE-LCF (5 mg/kg) n = 8, SE-LCF (10 mg/kg) n =7. Statistical 
comparison: ****, Control† vs SE-Veh†, p<0.0001; ***, SE-LCF (5 mg/kg) vs SE-LCF 
(10 mg/kg); ns, Control† vs SE-LCF (10 mg/kg), p>0.99; ANOVA with Tukey’s post-hoc 
analysis. 
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To assess if ZC could also prevent leakage in capillaries isolated from SE rats, 
confocal microscopy was used to measure the leakage rate of fluorescent Texas Red™ 
(Figure 18). TR leakage rates for capillaries of the SE-Veh group (0.6 ± 0.06) were similar 
to those of the positive control (100 mM mannitol, 0.7 ± 0.17). Conversely, isolated 
capillaries from the Pilo-Veh and Pilo-ZC rats had leakage rates equal to negative control 
capillaries (0.2 ± 0.13, 0.2 ± 0.08, and 0.2 ± 0.09, respectively). For SE rats dosed with 
zileuton and celecoxib, the leakage rate (0.2 ± 0.06) was also equal to control levels. 
Based on these data, which show decreased serum S100β concentrations and decreased 
capillary leakage rates in SE rats treated with zileuton and celecoxib, we conclude that 
inhibition of 5-LOX and COX-2 prevents SE-induced barrier leakage in vivo. 
 
  
Figure 17: 5 mg/kg Zileuton and 10 
mg/kg Celecoxib Prevent S100β Leakage 
After Status Epilepticus. Serum S100β 
concentrations were elevated for vehicle 
treated SE rats compared to controls and 
compared to rats that received pilocarpine 
but did not develop SE. Rats treated with 
ZC had significantly lower levels of serum 
S100β compared to SE rats which received 
vehicle. S100β concentrations measured as 
pg/ml; data are mean ± SEM; Ctrl n = 6; 
Pilo-Veh n = 8, Pilo-ZC n = 5, SE-Veh n = 7, 
SE-ZC n = 9. Statistical comparison: ****, 
Control vs SE-Veh, p<0.0001; ****, SE-Veh 
vs SE-ZC; ns, Control vs SE-LCF, p>0.99; 
ANOVA with Tukey’s post-hoc analysis. 
Figure 18: 5 mg/kg Zileuton and 10 
mg/kg Celecoxib Decreases Barrier 
Leakage in Brain Capillaries. The 
rate of Texas Red™ leakage from 
capillaries isolated from ZC treated SE 
rats was decreased to control levels. 
Luminal TR measured as arbitrary 
fluorescence units and first-order 
efflux rates were calculated by non-
linear regression. Efflux rates are 
shown as mean ± SEM for n = 7 
capillaries per time point for each 
group;   group sizes:  Ctrl n = 6; Pilo-
Veh n = 8, Pilo-ZC n = 5, SE-Veh n = 
7, SE-ZC n = 9. 
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4. Discussion 
 
4.1 Summary of Findings 
 The data in this thesis provide in vivo evidence that serum S100β is significantly 
elevated 48 hours after SE (Figures 11, 12, 14, 16, and 17). This finding is reproducible. 
Additionally, preliminary data were replicated that show capillaries isolated from rats 48 
hours post-SE are leakier than those of controls (Figures 13, 15, and 18). Taken together, 
we conclude that S100β is an effective surrogate marker for blood-brain barrier leakage. 
Knowing that this time point was useful for detecting an acute disruption of blood-brain 
barrier integrity, rats were treated with the dual LOX and COX inhibitor licofelone. 
However, no significant reduction in S100β levels or TR leakage rates were found in the 
SE treatment group compared to SE-Veh rats when licofelone was given at 5 mg/kg 
(Figures 12 and 13). Conversely, 10 mg/kg completely prevented the increased serum 
S100β and TR leakage seen in SE-Veh rats (Figures 14 and 15). These data suggest 
SE-induced blood-brain barrier leakage can be prevented by licofelone in a dose 
dependent manner and that this leakage involves LOX and COX (Figure 16). 
Furthermore, inhibition with the FDA-approved inhibitors zileuton and celecoxib show that 
barrier breakdown is mediated by the 5-LOX and COX-2 isoforms (Figure 17 and 18). 
These data show that inhibiting these enzymes reduced TR leakage to control rates in 
capillaries isolated from SE rats and also reduced S100β levels to that of controls.  
 
4.2 Findings in Context with Current Literature 
 In brain tissue, COX-2 mRNA and protein expression increase after seizures with 
protein expression peaking around 24 hours.74,75. COX-2 is an enzyme that generates 
prostaglandins and conflicting evidence shows that COX-2 inhibition may increase or 
decrease spontaneous seizure recurrence, mortality, and neuronal damage depending on 
the model used and whether the inhibitor was given before or after SE induction.76 COX-
2 is also present in brain capillaries, but protein expression remains unchanged when 
glutamate is applied ex vivo.62,63 Preliminary ex vivo data from this group (data not shown) 
suggest that ex vivo brain capillary leakage is prevented by inhibition of LOX and COX 
together, but not when either of these enzymes is inhibited alone. We conclude that both 
pathways for metabolizing arachidonic acid are involved in blood-brain barrier leakage. 
The effects 5-LOX and COX-2 in epilepsy have also been studied by others. Eslami and 
colleagues recently published work suggesting that licofelone decreases SE incidence.70 
Since we did not induce SE with a single high dose of pilocarpine, but instead used a 
fractionated multiple-dose method, we could not directly compare SE incidence. However, 
we did count the number of class 4 and 5 seizures across all SE inductions and found no 
difference between those treated with vehicle, licofelone, or zileuton with celecoxib (data 
not shown). 
One current hypothesis tying blood-brain barrier leakage to seizure recurrence in 
pharmacoresistant epilepsy is that extravasation of albumin into the brain decreases free 
antiepileptic drug concentration.77,78 If free antiepileptic drug decreases, drug efficacy may 
decrease as well. One hypothesis for epileptogenesis after blood-brain barrier leakage is 
that extravasation of albumin causes epileptogenesis through astrocytic 
transformation.57,79-84 These studies provide evidence that extravasation of albumin 
promotes ictogenesis by TGF-β mediated downregulation of inward rectifying potassium 
channels and glutamate transporters causing impaired buffering of extracellular potassium 
and glutamate. This is related to our work because currently, there are still knowledge 
gaps regarding what happens prior to albumin extravasation: the gap between a seizure 
event and blood-brain barrier leakage. Recent evidence published by our group show that 
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MMP protein expression and activity is increased after SE and levels of tight junctions 
decrease.64 Ex vivo preliminary data from this laboratory suggest these changes are 
mediated by glutamate acting on capillary NMDAR, cPLA2 arachidonic acid production, 5-
LOX, and COX-2. As stated above, we hypothesized that seizures trigger LOX and COX 
mediated blood-brain barrier leakage and that dual LOX/COX inhibition would prevent 
barrier leakage in vivo. The data herein demonstrate barrier leakage associated with 
seizures is mediated by 5-LOX and COX-2 – as evidenced by serum S100β levels and 
capillary TR leakage rates – and can be prevented by dual inhibition of these enzymes.  
The data presented here are consistent with clinical literature that states seizures 
are associated with a leaky blood-brain barrier as evidenced by immunohistochemistry 
and MRI.47,85 In sera collected from epilepsy patients, S100β concentrations are 
significantly elevated during seizures compared to sera collected before a seizure event.86 
In the acute seizure model used in this work, serum S100β is profoundly elevated in SE 
rats supporting it is a translatable model to use for mechanistic studies. With a growing 
body of literature supporting blood-brain barrier leakage causing seizures, these data 
would suggest that dual LOX and COX inhibition, such as with zileuton and celecoxib, may 
be an effective therapy to prevent seizure recurrence.47,56,87,88 While this study was 
designed to elucidate the molecular basis for blood-brain barrier opening after SE and 
identify 5-LOX and COX-2 as therapeutic targets, it was not intended to determine if a 
“treatment window” exists for these targets. However, Fabene and colleagues 
demonstrated that administration of adhesion molecule inhibitors after SE decreased 
polymorphonuclear cell adhesion, prevented barrier leakage after SE, and decreased 
seizure recurrence in SE.87 No data exists yet to support a “treatment window” for inhibition 
of 5-LOX and COX-2. Preliminary data from our laboratory (not shown) suggest that 
leukotriene B4, a downstream product of 5-LOX and chemokine for neutrophils, is elevated 
in plasma from SE rats and epilepsy patients. Additional studies are needed to determine 
if the LOX pathway is involved in cytokine release and neutrophil recruitment at the blood-
brain barrier in epilepsy.89,90 
 
4.3 Future Studies 
 These data provide noteworthy support for inhibition of 5-LOX and COX-2 to 
prevent of SE induced barrier leakage. However, there are still ways to bolster the validity 
of these data, the inhibition experiments can be repeated using endpoints such as MRI, 
cranial window surgery with multiphoton confocal microscopy and a fluorescent vascular 
marker, in situ brain perfusion with a radioactive vascular marker, and brain slice 
immunohistochemistry for albumin.57,58,91,92 Showing additional endpoints, with prevention 
of barrier leakage by inhibiting LOX and COX would enhance the impact of this study. 
Additional mechanistic studies could also be conducted with inhibitors of other targets that 
may be downstream of 5-LOX and COX-2. Inhibition of microsomal prostaglandin E2 
synthase 1 is one possible target of interest downstream from COX-2 and inhibitors for 
this enzyme are currently under development.93,94 The FDA-approved cysteinyl 
leukotrieine receptor 1 inhibitor montelukast could be used to inhibit the effects of 5-LOX 
downstream metabolites. However, this would not account for any actions of dihydroxyl-
leukotrienes such as LTB4: a chemokine for neutrophils which have been implicated in 
blood-brain barrier breakdown and seizure genesis in mice.87,95 5-LOX and COX-2 are 
early actors in the metabolism and action of leukotrienes and prostaglandins and 
additional mechanistic work may provide additional pharmacologic targets in seizure 
induced blood-brain barrier leakage.  
With evidence to show inhibition of LOX and COX preventing SE-induced barrier 
opening, the next question should be: does inhibition of LOX and COX prevent seizure 
recurrence? This would need to be investigated with a chronic epilepsy model (Hartz et 
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al., (2017). Mol Pharm).61 If LOX and COX inhibition used as disease modifying therapy 
added to antiseizure drugs decreases seizure recurrence in a chronic epilepsy model, it 
will also be important to investigate if chronic administration of LOX and COX inhibitor is 
necessary to decrease seizure recurrence or if acute administration after SE is sufficient.  
 
4.4 Translational Science Perspectives 
As mentioned above, this study was designed in such a way that rats were dosed 
with inhibitors beginning two days before the SE induction; it was designed specifically for 
mechanistic work and has limitations just as any model does. Knowing this, it might be 
useful to highlight two hurdles this work will face if translation to clinical use is considered: 
clinical study operations and dose determination. 
Since it is uncommon to use zileuton and celecoxib chronically, it is not foreseeable 
that a person would have two 4 doses of zileuton and celecoxib prior to a status epilepticus 
event. It would be clinically useful to know if beginning LOX and COX inhibition after 
seizure onset retains the ability to prevent barrier leakage. Therefore, as mentioned 
above, it will be important to establish a “treatment window” with numerous endpoint 
measures before considering a clinical study. If the effective window after SE is not long 
enough for patients to be easily enrolled, the study will struggle to meet adequate 
recruitment and it is essential to be able to demonstrate expected recruitment for success 
in obtaining funding.96  
A benchtop challenge to the translational utility of these data is the impact of 
interspecies variation on dosing. Zileuton and celecoxib are both highly protein bound and 
extensively metabolized by the liver.97 This complicates allometric dose scaling and 
additional pharmacokinetic modeling would be required to determine an appropriate dose 
for human study.98 However, celecoxib and zileuton are both FDA-approved and therefore, 
some inferences can be made based on our dosing scheme and pharmacokinetic data 
already published. For example, rats given a single oral dose of 10 mg/kg celecoxib results 
in an AUC0-∞ of 18.5 µg*h/ml and a single 400 mg oral dose in humans results in an AUC0-
∞ of 13.3 µg*h/ml.97 The pharmacology data in the FDA approval package also suggest 
incomplete absorption of celecoxib when given orally. This means parenteral 
administration, as conducted in this study, would result in even higher exposures 
compared to those seen above. Although single doses were studied up to 1200 mg in 
humans, safety of multiple high doses has not been established and the highest label-
approved regimen is 400 mg orally for one dose followed by 200 mg twice per day.97 It will 
be prudent for clinical researchers and institutional review boards to consider the risks vs. 
benefits of an acute course of higher dosed celecoxib and zileuton, in a neurologic crisis 
such as SE, if dose scaling suggests FDA labeled dosing would not provide efficacy. 
5. Conclusion 
 Current clinical and pre-clinical dogma states that seizures beget seizures and 
growing evidence support blood-brain barrier leakage as a contributing factor in this 
positive feedback loop. The data presented in this thesis provide compelling support for 
5-LOX- and COX-2-controlled blood-brain barrier leakage in an in vivo SE model. The 
utility of zileuton and celecoxib for prevention of blood-brain barrier leakage is significant 
because these medications are already FDA-approved. This field would benefit from 
additional study to investigating 5-LOX and COX-2 as therapeutic drug targets to prevent 
blood-brain barrier leakage in epilepsy.  
 
  
23 
References 
1. Zlokovic BV, Apuzzo ML. Strategies to circumvent vascular barriers of the central 
nervous system. Neurosurgery 1998;43:877-8. 
2. Zack MM, Kobau R. National and State Estimates of the Numbers of Adults and 
Children with Active Epilepsy - United States, 2015. MMWR Morbidity and mortality 
weekly report 2017;66:821-5. 
3. England MJ, Liverman CT, Schultz AM, Strawbridge LM. Summary: a reprint from 
epilepsy across the spectrum: promoting health and understanding. Epilepsy Curr 
2012;12:245-53. 
4. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. 
How common are the "common" neurologic disorders? Neurology 2007;68:326-
37. 
5. Kwan  P, Brodie  MJ. Early Identification of Refractory Epilepsy. New England 
Journal of Medicine 2000;342:314-9. 
6. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical 
clinical definition of epilepsy. Epilepsia 2014;55:475-82. 
7. Selassie AW, Wilson DA, Martz GU, Smith GG, Wagner JL, Wannamaker BB. 
Epilepsy beyond seizure: a population-based study of comorbidities. Epilepsy 
research 2014;108:305-15. 
8. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and 
risk of suicide: a population-based case-control study. The Lancet Neurology 
2007;6:693-8. 
9. Hermann B, Seidenberg M, Jones J. The neurobehavioural comorbidities of 
epilepsy: can a natural history be developed? The Lancet Neurology 2008;7:151-
60. 
10. Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and 
risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. 
Epilepsy & Behavior 2003;4:31-8. 
11. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status 
epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. 
Epilepsia 2015;56:1515-23. 
12. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and 
management of status epilepticus. Neurocritical care 2012;17:3-23. 
13. Glauser T, Shinnar S, Gloss D, et al. Evidence-Based Guideline: Treatment of 
Convulsive Status Epilepticus in Children and Adults: Report of the Guideline 
Committee of the American Epilepsy Society. Epilepsy Currents 2016;16:48-61. 
14. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for 
generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus 
Cooperative Study Group. N Engl J Med 1998;339:792-8. 
15. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, 
and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 
2001;345:631-7. 
16. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous 
therapy for prehospital status epilepticus. N Engl J Med 2012;366:591-600. 
17. Cock HR. Established status epilepticus treatment trial (ESETT). Epilepsia 
2011;52 Suppl 8:50-2. 
18. Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. 
Epilepsia 2013;54 Suppl 6:89-92. 
19. Cook AM, Castle A, Green A, et al. Practice variations in the management of status 
epilepticus. Neurocritical care 2012;17:24-30. 
24 
20. Ferlisi M, Hocker S, Grade M, Trinka E, Shorvon S. Preliminary results of the global 
audit of treatment of refractory status epilepticus. Epilepsy Behav 2015;49:318-24. 
21. DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status 
epilepticus. Journal of clinical neurophysiology : official publication of the American 
Electroencephalographic Society 1995;12:316-25. 
22. Lv RJ, Wang Q, Cui T, Zhu F, Shao XQ. Status epilepticus-related etiology, 
incidence and mortality: A meta-analysis. Epilepsy research 2017;136:12-7. 
23. Jafarpour S, Hodgeman RM, De Marchi Capeletto C, et al. New-Onset Status 
Epilepticus in Pediatric Patients: Causes, Characteristics, and Outcomes. 
Pediatric neurology 2017. 
24. Raspall-Chaure M, Chin RF, Neville BG, Scott RC. Outcome of paediatric 
convulsive status epilepticus: a systematic review. The Lancet Neurology 
2006;5:769-79. 
25. Vilella L, Gonzalez Cuevas M, Quintana Luque M, et al. Prognosis of status 
epilepticus in elderly patients. Acta neurologica Scandinavica 2018;137:321-8. 
26. Wu YW, Shek DW, Garcia PA, Zhao S, Johnston SC. Incidence and mortality of 
generalized convulsive status epilepticus in California. Neurology 2002;58:1070-
6. 
27. Gowers WR. Epilepsy and other Chronic Convulsive Diseases: Thier Causes, 
Symptoms, & Treatment. London: J. & A. Churchill; 1881. 
28. Lawn N, Chan J, Lee J, Dunne J. Is the first seizure epilepsy--and when? Epilepsia 
2015;56:1425-31. 
29. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: 
Management of an unprovoked first seizure in adults: Report of the Guideline 
Development Subcommittee of the American Academy of Neurology and the 
American Epilepsy Society. Neurology 2015;84:1705-13. 
30. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment Outcomes in Patients with Newly 
Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-
Year Longitudinal Cohort Study. JAMA neurology 2017. 
31. Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Risk of 
unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. 
Ann Neurol 1998;44:908-12. 
32. Verity CM, Ross EM, Golding J. Outcome of childhood status epilepticus and 
lengthy febrile convulsions: findings of national cohort study. BMJ (Clinical 
research ed) 1993;307:225-8. 
33. Cavazzuti GB, Ferrari P, Lalla M. Follow-up study of 482 cases with convulsive 
disorders in the first year of life. Developmental medicine and child neurology 
1984;26:425-37. 
34. Lewandowski M. Zur Lehre der Cerebrospinalflussigeit. Z Klin Med 1990;40:480-
94. 
35. Ehrlich P. Sauerstoff-Bedürfniss des Organismus Eine farbenanalytische Studie. 
Berlin: August Hirschwald 1885. 
36. Goldmann EE. Beitrag zur Physio-Pathologie des Plexus Chorioideus und der 
Hirnhäute. Abh Preuss Akad Wiss Physik 1913;1:1-60. 
37. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to 
exogenous peroxidase. The Journal of cell biology 1967;34:207-17. 
38. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes 
in the vertebrate brain. The Journal of cell biology 1969;40:648-77. 
39. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and Dysfunction of 
the Blood-Brain Barrier. Cell 2015;163:1064-78. 
25 
40. Tietz S, Engelhardt B. Brain barriers: Crosstalk between complex tight junctions 
and adherens junctions. The Journal of cell biology 2015;209:493-506. 
41. Merali Z, Huang K, Mikulis D, Silver F, Kassner A. Evolution of blood-brain-barrier 
permeability after acute ischemic stroke. PloS one 2017;12:e0171558. 
42. Jiang X, Andjelkovic AV, Zhu L, et al. Blood-brain barrier dysfunction and recovery 
after ischemic stroke. Progress in neurobiology 2017. 
43. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in 
Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 
2018;14:133-50. 
44. Marchi N, Teng Q, Ghosh C, et al. Blood-brain barrier damage, but not 
parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 
2010;1353:176-86. 
45. Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-
traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008;79:774-7. 
46. Rigau V, Morin M, Rousset MC, et al. Angiogenesis is associated with blood-brain 
barrier permeability in temporal lobe epilepsy. Brain : a journal of neurology 
2007;130:1942-56. 
47. van Vliet EA, da Costa Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA. 
Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. 
Brain : a journal of neurology 2007;130:521-34. 
48. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain 
barrier disruption. Epilepsia 2007;48:732-42. 
49. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-
arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: 
a multi-institutional experience. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2009;27:3503-9. 
50. Kiechle K, Bazarian JJ, Merchant-Borna K, et al. Subject-specific increases in 
serum S-100B distinguish sports-related concussion from sports-related exertion. 
PloS one 2014;9:e84977. 
51. Bouvier D, Duret T, Abbot M, et al. Utility of S100B Serum Level for the 
Determination of Concussion in Male Rugby Players. Sports medicine (Auckland, 
NZ) 2017;47:781-9. 
52. Meier TB, Nelson LD, Huber DL, Bazarian JJ, Hayes RL, McCrea MA. Prospective 
Assessment of Acute Blood Markers of Brain Injury in Sport-Related Concussion. 
Journal of neurotrauma 2017;34:3134-42. 
53. Petzold A, Green AJ, Keir G, et al. Role of serum S100B as an early predictor of 
high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 
2002;30:2705-10. 
54. Korfias S, Stranjalis G, Boviatsis E, et al. Serum S-100B protein monitoring in 
patients with severe traumatic brain injury. Intensive care medicine 2007;33:255-
60. 
55. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe 
Traumatic Brain Injury, Fourth Edition. Neurosurgery 2017;80:6-15. 
56. Seiffert E, Dreier JP, Ivens S, et al. Lasting blood-brain barrier disruption induces 
epileptic focus in the rat somatosensory cortex. J Neurosci 2004;24:7829-36. 
57. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake 
into astrocytes is involved in neocortical epileptogenesis. Brain : a journal of 
neurology 2007;130:535-47. 
58. van Vliet EA, Otte WM, Gorter JA, Dijkhuizen RM, Wadman WJ. Longitudinal 
assessment of blood-brain barrier leakage during epileptogenesis in rats. A 
quantitative MRI study. Neurobiology of disease 2014;63:74-84. 
26 
59. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous 
seizure in the conscious human brain. Lancet (London, England) 1993;341:1607-
10. 
60. Carlson H, Ronne-Engstrom E, Ungerstedt U, Hillered L. Seizure related 
elevations of extracellular amino acids in human focal epilepsy. Neuroscience 
letters 1992;140:30-2. 
61. Hartz AM, Pekcec A, Soldner EL, Zhong Y, Schlichtiger J, Bauer B. P-gp Protein 
Expression and Transport Activity in Rodent Seizure Models and Human Epilepsy. 
Molecular pharmaceutics 2017;14:999-1011. 
62. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H. Seizure-induced 
up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and 
cyclooxygenase-2 signaling. Molecular pharmacology 2008;73:1444-53. 
63. !!! INVALID CITATION !!! {}. 
64. Rempe RG, Hartz AMS, Soldner ELB, et al. Matrix Metalloproteinase-Mediated 
Blood-Brain Barrier Dysfunction in Epilepsy. J Neurosci 2018. 
65. Curia G, Longo D, Biagini G, Jones RSG, Avoli M. The pilocarpine model of 
temporal lobe epilepsy. Journal of Neuroscience Methods 2008;172:143-57. 
66. Jope RS, Morrisett RA, Snead OC. Characterization of lithium potentiation of 
pilocarpine-induced status epilepticus in rats. Experimental neurology 
1986;91:471-80. 
67. Honchar MP, Olney JW, Sherman WR. Systemic cholinergic agents induce 
seizures and brain damage in lithium-treated rats. Science (New York, NY) 
1983;220:323-5. 
68. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor 
seizure. Electroencephalography and clinical neurophysiology 1972;32:281-94. 
69. Koeberle A, Siemoneit U, Buhring U, et al. Licofelone suppresses prostaglandin 
E2 formation by interference with the inducible microsomal prostaglandin E2 
synthase-1. J Pharmacol Exp Ther 2008;326:975-82. 
70. Eslami SM, Moradi MM, Ghasemi M, Dehpour AR. Anticonvulsive Effects of 
Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a 
Role for Inducible Nitric Oxide Synthase. Journal of epilepsy research 2016;6:51-
8. 
71. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of P-glycoprotein at the 
blood-brain barrier by endothelin-1. Molecular pharmacology 2004;66:387-94. 
72. Hartz AM, Bauer B, Soldner EL, et al. Amyloid-beta contributes to blood-brain 
barrier leakage in transgenic human amyloid precursor protein mice and in humans 
with cerebral amyloid angiopathy. Stroke 2012;43:514-23. 
73. Marchi N, Rasmussen P, Kapural M, et al. Peripheral markers of brain damage 
and blood-brain barrier dysfunction. Restor Neurol Neurosci 2003;21:109-21. 
74. Joseph SA, Lynd-Balta E, O'Banion MK, et al. Enhanced cyclooxygenase-2 
expression in olfactory-limbic forebrain following kainate-induced seizures. 
Neuroscience 2006;140:1051-65. 
75. Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R. Therapeutic 
window for cyclooxygenase-2 related anti-inflammatory therapy after status 
epilepticus. Neurobiology of disease 2015;76:126-36. 
76. Radu BM, Epureanu FB, Radu M, Fabene PF, Bertini G. Nonsteroidal anti-
inflammatory drugs in clinical and experimental epilepsy. Epilepsy research 
2017;131:15-27. 
77. Marchi N, Betto G, Fazio V, et al. Blood-brain barrier damage and brain penetration 
of antiepileptic drugs: role of serum proteins and brain edema. Epilepsia 
2009;50:664-77. 
27 
78. Salar S, Maslarova A, Lippmann K, et al. Blood-brain barrier dysfunction can 
contribute to pharmacoresistance of seizures. Epilepsia 2014;55:1255-63. 
79. Friedman A, Heinemann U. Role of Blood-Brain Barrier Dysfunction in 
Epileptogenesis. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-
Escueta AV, eds. Jasper's Basic Mechanisms of the Epilepsies. 4th ed. Bethesda 
(MD)2012. 
80. Gorter JA, van Vliet EA, Aronica E. Status epilepticus, blood-brain barrier 
disruption, inflammation, and epileptogenesis. Epilepsy Behav 2015;49:13-6. 
81. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta 
signaling involvement in epileptogenesis. J Neurosci 2009;29:8927-35. 
82. David Y, Cacheaux LP, Ivens S, et al. Astrocytic dysfunction in epileptogenesis: 
consequence of altered potassium and glutamate homeostasis? J Neurosci 
2009;29:10588-99. 
83. Raabe A, Schmitz AK, Pernhorst K, et al. Cliniconeuropathologic correlations show 
astroglial albumin storage as a common factor in epileptogenic vascular lesions. 
Epilepsia 2012;53:539-48. 
84. Hinterkeuser S, Schroder W, Hager G, et al. Astrocytes in the hippocampus of 
patients with temporal lobe epilepsy display changes in potassium conductances. 
The European journal of neuroscience 2000;12:2087-96. 
85. Cole AJ. Status epilepticus and periictal imaging. Epilepsia 2004;45 Suppl 4:72-7. 
86. Bargerstock E, Puvenna V, Iffland P, et al. Is peripheral immunity regulated by 
blood-brain barrier permeability changes? PloS one 2014;9:e101477. 
87. Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial 
adhesion mechanisms in epilepsy. Nature medicine 2008;14:1377-83. 
88. Marchi N, Tierney W, Alexopoulos AV, Puvenna V, Granata T, Janigro D. The 
etiological role of blood-brain barrier dysfunction in seizure disorders. Cardiovasc 
Psychiatry Neurol 2011;2011:482415. 
89. Fabene PF, Bramanti P, Constantin G. The emerging role for chemokines in 
epilepsy. J Neuroimmunol 2010;224:22-7. 
90. Zattoni M, Mura ML, Deprez F, et al. Brain infiltration of leukocytes contributes to 
the pathophysiology of temporal lobe epilepsy. J Neurosci 2011;31:4037-50. 
91. Shih AY, Driscoll JD, Drew PJ, Nishimura N, Schaffer CB, Kleinfeld D. Two-photon 
microscopy as a tool to study blood flow and neurovascular coupling in the rodent 
brain. Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism 2012;32:1277-309. 
92. Smith QR, Allen DD. In situ brain perfusion technique. Methods in molecular 
medicine 2003;89:209-18. 
93. Koeberle A, Laufer SA, Werz O. Design and Development of Microsomal 
Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. Journal 
of medicinal chemistry 2016;59:5970-86. 
94. Jin Y, Smith CL, Hu L, et al. Pharmacodynamic comparison of LY3023703, a novel 
microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. Clinical 
pharmacology and therapeutics 2016;99:274-84. 
95. Yokomizo T, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal 
transduction. Archives of biochemistry and biophysics 2001;385:231-41. 
96. Cofield SS, Conwit R, Barsan W, Quinn J. Recruitment and retention of patients 
into emergency medicine clinical trials. Academic emergency medicine : official 
journal of the Society for Academic Emergency Medicine 2010;17:1104-12. 
97. Celebrex Approval Package. United States Food and Drug Administration 
2001;21-156. 
28 
98. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. 
British journal of pharmacology 2009;157:907-21. 
 
  
29 
Vita 
 
EDUCATION 
 
AWARDS 
Dean’s List 
University of Kentucky College of Pharmacy  
 
2017 
Kappa Psi Scholarship Honors Certificate 
 
2017 
Summer Research Program 
University of Kentucky College of Pharmacy 
 
2016 
Kappa Psi Scholarship Honors Certificate 
 
2016 
Dean’s List 
University of Kentucky College of Pharmacy 
2014 
 
PUBLICATIONS 
 
1. Rempe RG, Hartz AMS, Soldner ELB, Sokola BS, Alluri SR, Abner EL, Kryscio 
RJ, Pekcec A, Schlichtiger J, Bauer B. Matrix Metalloproteinase-Mediated 
Blood-Brain Barrier Dysfunction in Epilepsy. J Neurosci. epub ahead of print. 
2018 
 
2. Ma DW, Wang AC, Parikh I, Green SJ, Hoffman JD, Chipala G, Sokola BS, 
Bauer B, Hartz AMS, Lin AL. Early-Interventional Ketogenic Diet Enhances 
Brain Function and Alters Gut Microbiome in Healthy Mice. Sci. Rep. epub 
ahead of print. 2018. 
 
3. Hartz AMS, Schulz JA, Sokola BS, Edelmann S, Shen AN, El Seblani N, 
Rempe RG, Zhong Y, Bauer B. Isolation of Human Brain Capillaries. 
 Accepted – J Vis Exp. 
 
4. Sokola BS, Rempe RG, Hartz AMS, Carney K, Bauer B. LOX/COX Inhibition 
Restores Blood-Brain Barrier Function in Epilepsy.  
 Manuscript in preparation 
 
5. Hartz AMS, Schulz JA, Sokola BS, Samala R, Bauer B. Blood-Brain Barrier 
Transporter P-gp and BCRP are Regulated by PI3K/Akt Signaling 
 Manuscript in preparation 
Bachelor of Science in Cell and Molecular Biology 
University of Minnesota – Duluth 
Duluth, MN  
2009 – 2013 
GPA – 3.41 
 
